Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.39 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6554847 | 0.99 | F2 (0.39) | F2F10MEN1KMT2AITGB3 | |
| SCHEMBL6554459 | 0.91 | F10 (0.40) | F2F10PRSS1EPHX2KLKB1 | |
| Hydrochloric Acid SCHEMBL6555877 | 0.90 | F10 (0.39) | F2F10PRSS1EPHX2KLKB1 | |
| SCHEMBL7560179 | 0.90 | F10 (0.38) | F2F10PRSS1EPHX2KLKB1 | |
| Hydrochloric Acid SCHEMBL7584891 | 0.89 | F10 (0.38) | F2F10PRSS1EPHX2KLKB1 | |
| SCHEMBL7561457 | 0.89 | F10 (0.40) | F2F10MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL7563518 | 0.88 | F10 (0.39) | F2F10MEN1KMT2AGAA | |
| SCHEMBL5099628 | 0.86 | F10 (0.38) | F2F10ITGB3ITGA2BPRSS1 | |
| SCHEMBL6555900 | 0.85 | F10 (0.41) | F2F10PRSS1EPHX2KLKB1 | |
| Hydrochloric Acid SCHEMBL5089044 | 0.85 | F10 (0.38) | F2F10MEN1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | F2 3/4885F10 35/4885MEN1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.